Strides Pharma surges 11% on USFDA EIR for flagship facility in Bengaluru
The successful closure of the inspection further strengthens Strides' regulatory track record and reinforces the company's commitment to supplying high-quality pharma products to patients across globe
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.business-standard.com — the content belongs to Business Standard.
